The many facets of <scp>miR</scp>‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response

Favero, Andrea; Segatto, Ilenia; Perin, Tiziana; Belletti, Barbara

doi:10.1002/wrna.1659

Cited by 29 publications

(14 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, studies have confirmed that miRNA is involved in many biological activities, especially the cell proliferation and invasion of malignant tumors, and can be used as a therapeutic target for cancer treatment [ 20 ]. The important role of miRNA in the early diagnosis and prognosis of a series of cancers has been confirmed, such as miR-223 [ 21 ], miR-30a-5p [ 22 ], and miR-105 [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer

Miao

Qiu

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Background. The incidence and mortality of breast cancer in the world remain high. The function and important role of miR-451 and miR-506 in a series of cancers have been proved. The purpose of this research was to explore the clinical diagnosis and prognostic significance of miR-451 and miR-506 expression in breast cancer. Methods. Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect miR-451 and miR-506 expression in serum and tissues. The relationship of miR-451 and miR-506 with clinical parameters was determined by the chi-square test. Receiver operating characteristics (ROC) analysis was conducted to evaluate the diagnostic accuracy of miR-451 and miR-506 in breast cancer. In addition, we determined the prognostic performance of miR-451 and miR-506 using Kaplan–Meier survival assay. Results. The expression of miR-451 and miR-506 in breast cancer patients was significantly lower than that in healthy people. miR-451 and miR-506 expression decreased in breast cancer tissues compared with paracancerous tissue. High expression of miR-451 and miR-506 was associated with positive lymph node metastasis and late tumor node metastasis stage. Breast cancer patients with high miR-451 and miR-506 expression had lower five-year survival rate. The level of miR-451 and miR-506 expression showed high diagnostic accuracy for distinguishing breast cancer patients and healthy people. Conclusion. miR-451 and miR-506 could be used as biomarker for the diagnosis and prognosis of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer

Miao

Qiu

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

show abstract

“…By contrast, we observed that miR-223 inhibited HNMT expression. A recent review elaborated the complexities of this miRNA: it can act as either an oncomir or oncosuppressor [40]. Unlike miR-223, data concerning the role of miR-3065 in cancer have been relatively limited; however, miR-3065 was recently found to be a potential predictor of disease severity in ovarian cancer, along with its target ADH7 [41].…”

Section: Discussionmentioning

confidence: 99%

HNMT Upregulation Induces Cancer Stem Cell Formation and Confers Protection against Oxidative Stress through Interaction with HER2 in Non-Small-Cell Lung Cancer

Kuo

Lin

Wang

et al. 2022

IJMS

View full text Add to dashboard Cite

Background: The treatment of non-small-cell lung cancer (NSCLC) involves platinum-based chemotherapy. It is typically accompanied by chemoresistance resulting from antioxidant properties conferred by cancer stem cells (CSCs). Human epidermal growth factor receptor 2 (HER2) enhances CSCs and antioxidant properties in cancers, including NSCLC. Methods: Here, we elucidated the role of histamine N-methyltransferase (HNMT), a histamine metabolism enzyme significantly upregulated in NSCLC and coexpressed with HER2. HNMT expression in lung cancer tissues was determined using quantitative reverse transcription PCR (RT-qPCR). A publicly available dataset was used to determine HNMT’s potential as an NSCLC target molecule. Immunohistochemistry and coimmunoprecipitation were used to determine HNMT–HER2 correlations and interactions, respectively. HNMT shRNA and overexpression plasmids were used to explore HNMT functions in vitro and in vivo. We also examined miRNAs that may target HNMT and investigated HNMT/HER2′s role on NSCLC cells’ antioxidant properties. Finally, how HNMT loss affects NSCLC cells’ sensitivity to cisplatin was investigated. Results: HNMT was significantly upregulated in human NSCLC tissues, conferred a worse prognosis, and was coexpressed with HER2. HNMT depletion and overexpression respectively decreased and increased cell proliferation, colony formation, tumorsphere formation, and CSCs marker expression. Coimmunoprecipitation analysis indicated that HNMT directly interacts with HER2. TARGETSCAN analysis revealed that HNMT is a miR-223 and miR-3065-5p target. TBHp treatment increased HER2 expression, whereas shHNMT disrupted the Nuclear factor erythroid 2-related factor 2 (Nrf2)/ hemeoxygenase-1 (HO-1)/HER2 axis and increased reactive oxygen species accumulation in NSCLC cells. Finally, shHNMT sensitized H441 cells to cisplatin treatment in vitro and in vivo. Conclusions: Therefore, HNMT upregulation in NSCLC cells may upregulate HER2 expression, increasing tumorigenicity and chemoresistance through CSCs maintenance and antioxidant properties. This newly discovered regulatory axis may aid in retarding NSCLC progression and chemoresistance.

show abstract

“…Additionally, miR-223 is an anti-inflammatory microRNA that acts as a tumor suppressor in TNBC. The published literature has demonstrated that miRNA-223 expression is associated with NLRP3 inflammasome inhibition and the inhibition of cell cycle progression [ 99 , 100 ].…”

Section: Non-coding Rnas In Oncologymentioning

confidence: 99%

Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy

Balahura

Dinescu

Costache

2023

IJMS

View full text Add to dashboard Cite

During the past decade, researchers have investigated the molecular mechanisms of breast cancer initiation and progression, especially triple-negative breast cancer (TNBC), in order to identify specific biomarkers that could serve as feasible targets for innovative therapeutic strategies development. TNBC is characterized by a dynamic and aggressive nature, due to the absence of estrogen, progesterone and human epidermal growth factor 2 receptors. TNBC progression is associated with the dysregulation of nucleotide-binding oligomerization domain-like receptor and pyrin domain-containing protein 3 (NLRP3) inflammasome, followed by the release of pro-inflammatory cytokines and caspase-1 dependent cell death, termed pyroptosis. The heterogeneity of the breast tumor microenvironment triggers the interest of non-coding RNAs’ involvement in NLRP3 inflammasome assembly, TNBC progression and metastasis. Non-coding RNAs are paramount regulators of carcinogenesis and inflammasome pathways, which could help in the development of efficient treatments. This review aims to highlight the contribution of non-coding RNAs that support inflammasome activation and TNBC progression, pointing up their potential for clinical applications as biomarkers for diagnosis and therapy.

show abstract

The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response

Cited by 29 publications

References 120 publications

Clinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer

Clinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer

HNMT Upregulation Induces Cancer Stem Cell Formation and Confers Protection against Oxidative Stress through Interaction with HER2 in Non-Small-Cell Lung Cancer

Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy

Contact Info

Product

Resources

About